Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Wednesday that new data for IZERVAY (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be highlighted at the upcoming American Academy of Ophthalmology Annual Meeting (AAO 2025), held from 18-20 October in Orlando, Florida.

The presentation will feature long-term safety and efficacy results from the GATHER2 open-label extension study, real-world evidence on treatment patterns and safety of IZERVAY in the United States, and the latest findings on a structure-function link in GA via ellipsoid zone integrity and low-luminance deficit.

IZERVAY is approved for the treatment of GA in the United States and Japan, and remains investigational in other countries and regions.

IZERVAY is a prescription eye injection used to treat GA, the advanced form of dry AMD.

Astellas said that IZERVAY met its primary endpoint in the GATHER1 and GATHER2 clinical trials, both of which were randomised, double-masked, sham-controlled, multicentre Phase 3 clinical trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD.